GEORGETOWN, TX, USA I September 24, 2014 I Molecular Templates, Inc., a biopharmaceutical company focused on the discovery and development of a new class of targeted biologic therapies, announced today that it presented preclinical data in a poster presentation at the American Association for Cancer Research special conference, Hematologic Malignancies: Translating Discoveries to Novel Therapies, held September 20-23rd, 2014.
In a poster presentation entitled “In vivo Efficacy of a CD38-Specific Engineered Toxin Body” (Abstract A15), the company presented preclinical data highlighting the potent and specific anti-CD38 effects of a lead compound in development for the treatment of hematological malignancies. The poster was highlighted in an AACR news release (http://www.aacr.org/Newsroom/Pages/News-Release-Detail.aspx?ItemID=601#.VCGxkvldWPs).
“We are excited to present preclinical data that demonstrate the unique capabilities of our platform technology,” said Eric Poma, CEO and CSO, Molecular Templates. “Our technology represents a new class of targeted therapies with distinct advantages over traditional antibody drug conjugates (ADCs). Our lead compound, MT-3724, will enter clinical studies this year for lymphoma and our CD38 program is advancing toward the clinic as well.”
About Molecular Templates
Molecular Templates is a venture-backed biopharmaceutical company focused on the discovery and development of a new class of targeted biologic therapeutics with distinct advantages over existing Antibody Drug Conjugates (ADCs). This biologic platform technology is being used to develop multiple therapies across a wide range of cancers. The Company’s lead compound, MT-3724, an immunotoxin targeting CD20, will initiate a Phase I study for the treatment of non-Hodgkin’s lymphoma this year. For more information, please visit www.moleculartemplates.com.
SOURCE: Molecular Templates
